Recent Finacing
Recent Raise
Origo Biopharma develops locally acting TGF‑beta inhibitor therapeutics for fibrosis and oncology, focusing on Crohn’s-associated gastrointestinal fibrosis, idiopathic pulmonary fibrosis, and colorectal cancer while minimizing systemic TGF‑beta adverse effects.
